The OctreoPharm Sciences GmbH (OPS) is a biopharmaceutical company in the fields of radioactively labeled pharmaceuticals. The company focuses in particular on the development of new radiopharmaceuticals for neuroendocrine tumors.
Its products will intend to improve the lives of patients through timely and accurate detection, effective monitoring of therapeutic response, disease progression and an improved treatment.
2011, October 12th
OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan® for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.more >>
2011, October 6th
OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.